New Study Finds Connection Between JAK Inhibitors & Heart Injuries
On September 1st, 2021, the U.S. Food and Drug Administration (FDA) issued a Drug Safety Communication to the public after reviewing a safety clinical trial into the safety of the medication Xeljanz. The FDA concluded that there is an increased risk of serious heart-related events such as heart attack or stroke, cancer, blood clots, and death…